NCT06351371 2026-04-14
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
341 trialsNCT02535312 2026-04-13
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT06136897 2026-04-13
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06360588 2026-04-13
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03744468 2026-04-02
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeOne Medicines
Phase 1/2 Completed
NCT03126630 2026-04-01
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT01064648 2026-03-31
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT04380753 2026-03-25
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
Amgen
Phase 1 Completed
NCT04083976 2026-03-19
RAGNAR
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT02959463 2026-03-06
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT02499328 2026-02-11
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
AstraZeneca
Phase 1/2 Completed
NCT04166734 2026-02-04
MESO-PRIME
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT04999969 2026-02-03
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
AstraZeneca
Phase 2 Active not recruiting
NCT04504942 2026-01-23
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
Phase 2 Completed
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05388058 2026-01-16
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
Phase 2 Completed
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05245682 2026-01-08
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Emory University
Phase EARLY_PHASE1 Active not recruiting
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT05047536 2025-12-19
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Terminated
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03388632 2025-12-18
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04381650 2025-12-10
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Completed
NCT05147272 2025-12-05
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Debiopharm International SA
Phase 1 Terminated
NCT05147350 2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1 Terminated
NCT06232408 2025-11-21
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Repare Therapeutics
Phase 1 Terminated
NCT03228537 2025-11-10
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT05322408 2025-11-05
HCW9218 in Select Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT03770494 2025-11-04
A Study of LY3405105 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT04972110 2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2 Terminated
NCT01375114 2025-10-28
The Effects of Ginseng on Cancer-Related Fatigue
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT05976334 2025-10-06
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
Phase 1 Terminated
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT01239381 2025-09-30
Individualized Stereotactic Body Radiotherapy of Liver Metastases
Massachusetts General Hospital
Phase NA Completed
NCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed
NCT05072106 2025-09-16
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT03195478 2025-09-15
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00186888 2025-09-04
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
St. Jude Children's Research Hospital
Phase 3 Completed
NCT05063318 2025-09-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT05014828 2025-08-24
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT04047862 2025-08-22
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT04596384 2025-08-19
Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery
City of Hope Medical Center
Phase NA Active not recruiting
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed